Designer drugs 2015: assessment and management
暂无分享,去创建一个
[1] R. McLay,et al. Psychosis associated with synthetic cannabinoid agonists: a case series. , 2011, The American journal of psychiatry.
[2] Arshid Mir,et al. Myocardial Infarction Associated With Use of the Synthetic Cannabinoid K2 , 2011, Pediatrics.
[3] D. Thornley‐Brown,et al. AKI associated with synthetic cannabinoids: a case series. , 2013, Clinical journal of the American Society of Nephrology : CJASN.
[4] S. Schnoll,et al. Role of the primary care physician in problems of substance abuse. , 1999, Archives of internal medicine.
[5] Tracy L. Brewer,et al. A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. , 2014, Journal for specialists in pediatric nursing : JSPN.
[6] S. R. Rose,et al. A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug , 2013, Clinical toxicology.
[7] Simon D Brandt,et al. Analyses of second-generation 'legal highs' in the UK: initial findings. , 2010, Drug testing and analysis.
[8] E. Nunes,et al. Treatment of Co-occurring Depression and Substance Dependence: Using Meta-analysis to Guide Clinical Recommendations. , 2008, Psychiatric annals.
[9] H. Haughey,et al. A Survey of Synthetic Cannabinoid Consumption by Current Cannabis Users , 2014, Substance abuse.
[10] M. Barratt,et al. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. , 2013, Drug and alcohol dependence.
[11] L. King,et al. A brief history of 'new psychoactive substances'. , 2011, Drug testing and analysis.
[12] Simon H. L. Thomas,et al. Severe clinical toxicity associated with analytically confirmed recreational use of 25I–NBOMe: case series , 2013, Clinical toxicology.
[13] Be Vang Dean,et al. 2C or Not 2C: Phenethylamine Designer Drug Review , 2013, Journal of Medical Toxicology.
[14] N. Ferreirós,et al. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? , 2009, Journal of mass spectrometry : JMS.
[15] A. Lewin,et al. High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand. , 2008, Bioorganic & medicinal chemistry.
[16] Christopher Y Hopkins,et al. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. , 2013, The Journal of emergency medicine.
[17] D J Nutt,et al. A web-based survey on mephedrone. , 2011, Drug and alcohol dependence.
[18] Gordon S. Smith,et al. Sociodemographic Characteristics Associated with Substance Use Status in a Trauma Inpatient Population , 2007, Journal of addictive diseases.
[19] R. Cook,et al. College students and use of K2: an emerging drug of abuse in young persons , 2011, Substance abuse treatment, prevention, and policy.
[20] J. Maxwell. Psychoactive substances--some new, some old: a scan of the situation in the U.S. , 2014, Drug and alcohol dependence.
[21] Rebecca Lynn Johnson,et al. Current "legal highs". , 2013, The Journal of emergency medicine.
[22] A. Kazory,et al. Synthetic marijuana and acute kidney injury: an unforeseen association , 2013, Clinical kidney journal.
[23] R. Bilici. Synthetic cannabinoids , 2014, Northern clinics of Istanbul.
[24] Patrick O'Malley,et al. Monitoring the Future national survey results on drug use, 1975-2018: Overview, key findings on adolescent drug use , 2015 .
[25] Kathryn Yung,et al. Spice, bath salts, and the U.S. military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. Armed Forces. , 2012, Military medicine.
[26] J. Ramsey,et al. Purchasing 'legal highs' on the Internet--is there consistency in what you get? , 2010, QJM : monthly journal of the Association of Physicians.
[27] M. Barratt,et al. The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample , 2014, Journal of psychopharmacology.
[28] S. Dursun,et al. Neurological complications of psychiatric drugs: clinical features and management , 2008, Human psychopharmacology.
[29] Anneke Poortman,et al. Instability of the ecstasy market and a new kid on the block: mephedrone , 2011, Journal of psychopharmacology.
[30] R. Vandrey,et al. A survey study to characterize use of Spice products (synthetic cannabinoids). , 2012, Drug and alcohol dependence.
[31] Elizabeth L. Ogburn,et al. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. , 2007, Archives of general psychiatry.
[32] Henry A Spiller,et al. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States , 2011, Clinical toxicology.
[33] I. Vardakou,et al. Drugs for youth via Internet and the example of mephedrone. , 2011, Toxicology letters.
[34] M. Galanter,et al. The American Psychiatric Publishing Textbook of Substance Abuse Treatment 4Ed , 2008 .
[35] J. Kelly,et al. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. , 2011, Drug testing and analysis.
[36] Lineke Zuurman,et al. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. , 2006, Journal of pharmaceutical sciences.
[37] Erik W. Gunderson,et al. Synthetic Cannabinoids: A New Frontier of Designer Drugs , 2013, Annals of Internal Medicine.
[38] J. O'Riordan,et al. A harmless high? , 2010, The Lancet.
[39] V. Auwärter,et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. , 2013, Addiction.
[40] J. Kornhuber,et al. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes , 2010, Schizophrenia Research.
[41] Wayne Hall,et al. Substance-Related Disorders , 2001 .
[42] Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final Order. , 2011, Federal register.
[43] C. Neighbors,et al. Spicing up the military: Use and effects of synthetic cannabis in substance abusing army personnel. , 2014, Addictive behaviors.
[44] A T McLellan,et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. , 2000, JAMA.
[45] Simon L Hill,et al. Clinical toxicology of newer recreational drugs , 2011, Clinical toxicology.
[46] A. Obafemi,et al. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. , 2012, The American journal of emergency medicine.
[47] G. Lloyd. Textbook of Psychosomatic Medicine , 2006, British Journal of Psychiatry.
[48] R. Spanagel,et al. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". , 2009, Deutsches Arzteblatt international.
[49] C. R. Harris,et al. Synthetic cannabinoid intoxication: a case series and review. , 2013, The Journal of emergency medicine.
[50] A. Winstock,et al. Mephedrone, new kid for the chop? , 2011, Addiction.
[51] Kurt R. Lehner,et al. Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive ‘Bath Salts’ Products , 2013, Neuropsychopharmacology.
[52] D. Basu,et al. Club drugs: review of the ‘rave’ with a note of concern for the Indian scenario , 2011, The Indian journal of medical research.
[53] C. Kang,et al. Three cases of “spice” exposure , 2011, Clinical toxicology.
[54] R. Lindigkeit,et al. Spice: a never ending story? , 2009, Forensic science international.
[55] Y. Goda,et al. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. , 2010, Forensic science international.
[56] W. Fratta,et al. Beyond THC: The New Generation of Cannabinoid Designer Drugs , 2011, Front. Behav. Neurosci..
[57] R. Rothman,et al. The Designer Methcathinone Analogs, Mephedrone and Methylone, are Substrates for Monoamine Transporters in Brain Tissue , 2012, Neuropsychopharmacology.
[58] Morna L Gonsoulin,et al. Pathological Findings in 2 Cases of Fatal 25I-NBOMe Toxicity , 2014, The American journal of forensic medicine and pathology.
[59] P. Dargan,et al. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. , 2010, QJM : monthly journal of the Association of Physicians.
[60] J. Maxwell,et al. Profiles of Club Drug Users in Treatment , 2005, Substance use & misuse.
[61] J. Poklis,et al. Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. , 2014, Forensic science international.
[62] I. Vardakou,et al. Spice drugs as a new trend: mode of action, identification and legislation. , 2010, Toxicology letters.
[63] P. Wax,et al. The Toxicology Investigators Consortium Case Registry—The 2011 Experience , 2012, Journal of Medical Toxicology.
[64] J. Ramsey,et al. Mephedrone: use, subjective effects and health risks. , 2011, Addiction.
[65] Barbara S. McCrady,et al. Addictions: A Comprehensive Guidebook , 2013 .
[66] M. Kirkpatrick,et al. Substituted cathinone products: a new trend in "bath salts" and other designer stimulant drug use. , 2013, Journal of addiction medicine.
[67] H. Haughey,et al. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. , 2012, The American journal on addictions.
[68] P. Gahlinger,et al. Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine. , 2004, American family physician.
[69] T. Woo,et al. "How high do they look?": identification and treatment of common ingestions in adolescents. , 2013, Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.
[70] L. Zamengo,et al. Determination of illicit drugs in seized materials: role of sampling and analysis in estimation of measurement uncertainty. , 2011, Forensic science international.